| Brandi Clary, MS CCC SLP | |
|
3545 S National Ave, Springfield, MO 65807-7310 | |
| (417) 269-4601 | |
| Not Available |
| Full Name | Brandi Clary |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 3545 S National Ave, Springfield, Missouri |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003394362 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 2016017138 (Missouri) | Primary |
| Provider Name | Lester E Cox Medical Centers |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1538334396 PECOS PAC ID: 1254248917 Enrollment ID: O20050624000293 |
News Archive
McCord Research, Inc., founded by Darlene McCord, Ph.D., FAPWCA, has produced a valuable guide to help people with diabetes take care of their feet for a lifetime. Dr. McCord has over 30 years of experience in the skin and wound care industry. Ten years ago she also created the most successful skin and wound care product line in North America.
Novartis Pharmaceuticals Corporation today announced that once-daily Arcapta Neohaler (indacaterol inhalation powder) 75 mcg is now available in the US and in pharmacies nationwide.
On Dec. 21, the U.S. Food and Drug Administration approved Juxtapid (lomitapide) to reduce low-density lipoprotein (LDL) cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol in patients with homozygous familial hypercholesterolemia (HoFH). Juxtapid is intended for use in combination with a low fat diet and other lipid-lowering treatments.
The largest trial into the use of Electroconvulsive Therapy in the UK in more than 30 years will look into how the use of the Class C drug ketamine might reduce the side effects of ECT for those being treated for severe depression.
Symyx Technologies, Inc. today announced it has joined the Pistoia Alliance, a non-profit group that promotes collaboration to streamline non-competitive elements of pharmaceutical and life science discovery workflows. The alliance was initially formed by major global pharmaceutical companies including Pfizer, GlaxoSmithKline, Novartis, and AstraZeneca.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brandi Clary, MS CCC SLP Po Box 4046, Springfield, MO 65808-4046 Ph: (417) 269-5712 | Brandi Clary, MS CCC SLP 3545 S National Ave, Springfield, MO 65807-7310 Ph: (417) 269-4601 |
News Archive
McCord Research, Inc., founded by Darlene McCord, Ph.D., FAPWCA, has produced a valuable guide to help people with diabetes take care of their feet for a lifetime. Dr. McCord has over 30 years of experience in the skin and wound care industry. Ten years ago she also created the most successful skin and wound care product line in North America.
Novartis Pharmaceuticals Corporation today announced that once-daily Arcapta Neohaler (indacaterol inhalation powder) 75 mcg is now available in the US and in pharmacies nationwide.
On Dec. 21, the U.S. Food and Drug Administration approved Juxtapid (lomitapide) to reduce low-density lipoprotein (LDL) cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol in patients with homozygous familial hypercholesterolemia (HoFH). Juxtapid is intended for use in combination with a low fat diet and other lipid-lowering treatments.
The largest trial into the use of Electroconvulsive Therapy in the UK in more than 30 years will look into how the use of the Class C drug ketamine might reduce the side effects of ECT for those being treated for severe depression.
Symyx Technologies, Inc. today announced it has joined the Pistoia Alliance, a non-profit group that promotes collaboration to streamline non-competitive elements of pharmaceutical and life science discovery workflows. The alliance was initially formed by major global pharmaceutical companies including Pfizer, GlaxoSmithKline, Novartis, and AstraZeneca.
› Verified 7 days ago
Ms. Ellen C Catt, MS,CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4518 S Frisco Trail Rd, Springfield, MO 65810 Phone: 417-459-3717 | |
Christina Zapata, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1610 E Sunshine St, Springfield, MO 65804 Phone: 417-523-7500 | |
Virginia Mclaughlin, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1235 E Cherokee St, Springfield, MO 65804 Phone: 417-576-3741 | |
Renea Franklin, SLP, CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1610 E. Sunshine Street, Springfield, MO 65804 Phone: 417-523-7500 Fax: 417-523-7595 | |
Ms. Megan Blake, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 639 W Chestnut Expy, Springfield, MO 65802 Phone: 417-895-9012 | |
Lindsey D Pindris, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1610 E Sunshine Street, Springfield, MO 65804 Phone: 417-523-7500 |